PDCD1 and glioma: In preclinical murine glioma models, combined PD-1 blockade and stereotactic radiosurgery (SRS) have been shown to improve antitumor immunity and produce long-term survivors [63, 64] and this concept is now in early clinical testing in patients with malignant brain tumours.